The definition of comprehensive non-small cell lung cancer (NSCLC) testing is rapidly evolving with new biomarkers and therapies, according to Julia Rotow, MD, creating added challenges for community practices.
Julia Rotow, MD
Advertisement
https://www.dana-farber.org/find-a-doctor/julia-rotow
Articles by Julia Rotow, MD
In this first part of an interview with The American Journal of Managed Care®, Julia Rotow, MD, thoracic oncologist at Dana-Farber Cancer Institute, discusses the critical need to test for biomarkers to afford patients the chance to benefit from recent treatment advances.
Advertisement
Latest Updated Articles
Health System Fragmentation Undermines Timely Lung Cancer Testing: Julia Rotow, MDPublished: July 31st 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
3
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
4
Combination Therapy Proves More Effective in NSCLC Compared With Chemotherapy
5
